Reversal of Anticoagulation in a True Emergency – An Update
Please see prior post here: http://www.emdocs.net/reversal-of-anticoagulation/
On October 16, 2015 the FDA granted accelerated approval of idarucizumab (Praxbind), a novel reversal agent of the direct thrombin inhibitor Dabigatran (Pradaxa), for utilization in life-threatening bleeding emergencies.1
Reversal of Anticoagulation in a True Emergency – An Update Read More »